Device Trial Radar · NCT04793711
EpiCeram for Skin Protection in Healthcare Workers
Last checked: Nov 20, 2026Latest source record: Aug 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1
Actual
Start
Mar 15, 2021
Primary completion
Jul 1, 2021
Study completion Jul 1, 2021
Sponsor
- Lead sponsor
- Primus PharmaceuticalsNot on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 11, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label study using a device currently prescribed by doctors. This means everyone involved in the study will know the name of the product, only one product will be used, and the U.S. Food and Drug Administration (FDA) has approved the sale of this product. Although this is called a device, the product is an emollient-type lotion. Healthcare workers (HCW) often suffer from signs and symptoms of skin irritation, including pain, redness, roughness, dryness, cracking and itching due to the extensive use of personal protective equipment (PPE) such as masks and gloves. These are thought to be due to changes in the normal skin barrier function induced by repeated minor abrasion in the warm, moist environment induced by extensive use of PPE required at work. EpiCeram Controlled Skin Barrier Emulsion (EpiCeram) is a prescription skin barrier repair product containing ingredients designed to improve skin barrier function. However, EpiCeram has not previously been studied in people with skin irritation due to extensive use of PPE. This study was terminated after 1 (one) subject was enrolled due to the inability to find willing participants.
Conditions
- Irritant Contact Dermatitis
Interventions
EpiCeramDevice
protective emollient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Patient Reported Outcome of Overall Skin Irritation SymptomsTime frame: Baseline to Day 28
- Change in Patient Reported Outcome of PainTime frame: Baseline to Day 28
- Change in Patient Reported Outcome of RednessTime frame: Baseline to Day 28
4 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Valley Arthritis Center
Peoria, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.